Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
Status:
Completed
Trial end date:
2024-04-05
Target enrollment:
Participant gender:
Summary
Miebo (Perfluorohexyloctane) is a novel, non-aqueous, single entity, preservative free,
ophthalmic drop. This drop was recently approved by the Food and Drug Administration (FDA)
for the treatment of Meibomian Gland Disease (MGD).
All published data on Miebo has been done in non-contact lens wearers. As contact lens
dropout rates seem to be an ongoing problem for practitioners, we are performing this study
utilizing this novel new drug with contact lens patients to determine if the drops assist
comfort in typical soft contact lens wearing patients. If the study determines that Miebo
assists in the overall comfort of contact lens patients this could be a possible way to help
keep patients in their contact lenses longer.